SCHEMBL30765600

SCHEMBL30765600

CCCCOC(=O)Cn1c(SC)ncc(NCc2ccc(OC)cc2OC)c1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 1/20 0.44
MAPT P10636 4/20 0.42
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
FLT3 P36888 1/20 0.39
TYRO3 Q06418 1/20 0.39
MERTK Q12866 1/20 0.39
GAS6 Q14393 1/20 0.39
ALDH1A1 P00352 1/20 0.38
TSHR P16473 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
EGLN1 Q9GZT9 3/20 0.38
GAA P10253 2/20 0.38
CNR1 P21554 1/20 0.38
CNR2 P34972 1/20 0.38
TP53 P04637 1/20 0.38
LMNA P02545 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
PDE9A O76083 2/20 0.38
CYP1A2 P05177 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765723 0.92 MAPT (0.47) KDM4CMAPTMEN1KMT2AALDH1A1
SCHEMBL30765933 0.86 KDM4C (0.45) KDM4CMAPTALDH1A1TSHRNPSR1
SCHEMBL30765741 0.85 LMNA (0.41) MAPTMEN1KMT2AALDH1A1LMNA
SCHEMBL30765668 0.85 GAA (0.50) KDM4CMAPTMEN1KMT2AALDH1A1
SCHEMBL30765999 0.82 PDE4B (0.44) KDM4CMAPTMEN1KMT2AFLT3
SCHEMBL30766080 0.80 MEN1 (0.45) MAPTMEN1KMT2AALDH1A1TSHR
SCHEMBL30765606 0.77 MEN1 (0.44) KDM4CMAPTMEN1KMT2AALDH1A1
SCHEMBL30765891 0.75 GAA (0.40) MAPTMEN1KMT2AALDH1A1TSHR
SCHEMBL30765661 0.73 MEN1 (0.48) MAPTMEN1KMT2AALDH1A1TSHR
SCHEMBL30765482 0.71 KDM4C (0.50) KDM4CMAPTMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed